GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback